Published in Vaccine Weekly, November 8th, 2000
University of Alabama, Birmingham, researcher De-chu Tang, PhD, is awaiting U.S. Food and Drug Administration approval for human trials of influenza and tetanus vaccines. The vaccine would be swabbed on the skin and covered temporarily with an adhesive patch. Eventually, the vaccine could be incorporated into the patch.
Tang invented the skin-targeted vaccine patch technology and demonstrated that it is a "remote control" for creating an immune reaction in skin cells.
"A biological army in the skin is constantly mobilized to ward off...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.